{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:45:12Z","timestamp":1792075512188,"version":"4.4.0"},"reference-count":39,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Evidence on cancer drug wastage comes largely from high-income countries and generally excludes the pediatric setting. This study quantified consumption, leftover reuse and wastage in a chemotherapy compounding unit of the Brazilian public health system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Prospective, observational, descriptive study covering every compounding episode performed between October and December 2024 in a public hospital serving adult oncology and adult and pediatric onco-hematology. Of 32 formulary injectable cytotoxic drugs, the 29 with activity were analyzed by quantity and cost. The daily balance was classified as reusable leftover or wastage by a 24-h stability threshold. Relative wastage (quantity discarded divided by quantity compounded) was calculated per drug.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>1298 patients were treated in 2030 compounding episodes. Compounded doses totaled 612,192\u2005mg or IU (BRL 657,724.73), of which 5.5% by quantity came from reused leftovers. Wastage reached 53,996.45\u2005mg or IU (BRL 30,391.78; USD 5206.84), equivalent to 8.8% of the compounded quantity, 4.6% of its value and 13.9\u2005mg or IU per patient treated per month. Fluorouracil led both compounded quantity (29.5%) and wastage (27.1%), yet relative wastage was highest in low-volume drugs with short stability: fludarabine (158.9%), etoposide (134.0%) and azacitidine (95.5%). Pegaspargase, used predominantly in children, combined 57.5% relative wastage with the largest discard cost (BRL 15,402.00). Pertuzumab, the costliest drug compounded, generated none.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Wastage concentrated in drugs with short stability and vial sizes poorly matched to prescribed doses, whereas the greatest financial impact fell on high unit-cost biologics. Relative wastage reveals intervention targets that absolute volume does not.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552261497394","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:59:37Z","timestamp":1791910777000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Wastage of injectable anticancer drugs in a public hospital chemotherapy compounding unit: A prospective descriptive study"],"prefix":"10.1177","author":[{"given":"Gabrielli De Lima","family":"Macedo","sequence":"first","affiliation":[{"name":"Residency Program in Hospital Pharmacy, Universidade Federal Fluminense, Niter\u00f3i, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Claudia De Almeida","family":"Ribeiro","sequence":"additional","affiliation":[{"name":"Ministry of Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1234-1262","authenticated-orcid":false,"given":"Andr\u00e9 Teixeira","family":"Pontes","sequence":"additional","affiliation":[{"name":"Universidade Federal do Rio Grande do Sul (UFRGS)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,10,13]]},"reference":[{"key":"e_1_3_3_2_2","volume-title":"Carga global de c\u00e2ncer aumenta em meio \u00e0 crescente necessidade de servi\u00e7os [Global cancer burden rises amid growing need for services] [Internet]","author":"Pan American Health Organization","year":"2024","unstructured":"Pan American Health Organization. Carga global de c\u00e2ncer aumenta em meio \u00e0 crescente necessidade de servi\u00e7os [Global cancer burden rises amid growing need for services] [Internet]. Washington (DC): PAHO, 2024, https:\/\/www.paho.org\/pt\/noticias\/1-2-2024-carga-global-cancer-aumenta-em-meio-crescente-necessidade-servicos (accessed 15 March 2025)."},{"key":"e_1_3_3_3_2","article-title":"Estimativa de incid\u00eancia de c\u00e2ncer no Brasil, 2023\u20132025 [Cancer incidence estimate in Brazil, 2023\u20132025]","volume":"69","author":"Santos MO","year":"2023","unstructured":"Santos MO, Lima FCS, Martins LFL, et al. Estimativa de incid\u00eancia de c\u00e2ncer no Brasil, 2023\u20132025 [Cancer incidence estimate in Brazil, 2023\u20132025]. Rev Bras Cancerol 2023; 69: e-213700.","journal-title":"Rev Bras Cancerol"},{"key":"e_1_3_3_4_2","volume-title":"Apenas 3% dos recursos da sa\u00fade foram gastos com c\u00e2ncer no SUS [Only 3% of health resources were spent on cancer in the SUS] [Internet]","author":"National Council of Health Secretaries (CONASS)","year":"2023","unstructured":"National Council of Health Secretaries (CONASS). Apenas 3% dos recursos da sa\u00fade foram gastos com c\u00e2ncer no SUS [Only 3% of health resources were spent on cancer in the SUS] [Internet]. Rio de Janeiro: CONASS, 2023, https:\/\/www.conass.org.br\/apenas-3-dos-recursos-da-saude-foram-gastos-com-cancer-no-sus-mais-dados-ineditos-no-8o-big-data-em-oncologia-em-13-6\/ (accessed 15 March 2025)."},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2024.08.006"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1177\/10781552231178678"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.12991\/jrespharm.1651278"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vhri.2026.101595"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.scitotenv.2017.05.115"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.14488\/BJOPM.2015.v12.n1.a14"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1177\/10781552251318313"},{"key":"e_1_3_3_12_2","unstructured":"Brazil. Ministry of Health. Brazilian Health Regulatory Agency (ANVISA). Resolu\u00e7\u00e3o RDC n\u00b0 220 de 21 de setembro de 2004 [Collegiate Board Resolution No. 220 of 21 September 2004]. Approves the technical regulation for the operation of antineoplastic therapy services. Di\u00e1rio Oficial da Uni\u00e3o. 21 Sep 2004."},{"key":"e_1_3_3_13_2","unstructured":"Brazil. Ministry of Health. Brazilian Health Regulatory Agency (ANVISA). Resolu\u00e7\u00e3o RDC n\u00b0 222 de 28 de mar\u00e7o de 2018 [Collegiate Board Resolution No. 222 of 28 March 2018]. Regulates good practices in the management of health service waste. Di\u00e1rio Oficial da Uni\u00e3o. 28 Mar 2018."},{"key":"e_1_3_3_14_2","first-page":"1558","article-title":"O uso de indicadores de qualidade e desempenho para evitar custos e desperd\u00edcios de medicamentos na farm\u00e1cia hospitalar [the use of quality and performance indicators to avoid drug costs and wastage in hospital pharmacy]","volume":"8","author":"Teixeira CAL","year":"2022","unstructured":"Teixeira CAL, Andrade LG. O uso de indicadores de qualidade e desempenho para evitar custos e desperd\u00edcios de medicamentos na farm\u00e1cia hospitalar [the use of quality and performance indicators to avoid drug costs and wastage in hospital pharmacy]. Rev Ibero-Am Humanid Cienc Educ 2022; 8: 1558\u20131566.","journal-title":"Rev Ibero-Am Humanid Cienc Educ"},{"key":"e_1_3_3_15_2","unstructured":"Brazil. Ministry of Health. Brazilian Health Regulatory Agency (ANVISA). Resolu\u00e7\u00e3o RDC n\u00b0 67 de 8 de outubro de 2007 [Collegiate Board Resolution No. 67 of 8 October 2007]. Provides for good compounding practices for magistral and officinal preparations for human use in pharmacies. Di\u00e1rio Oficial da Uni\u00e3o. 8 Oct 2007."},{"key":"e_1_3_3_16_2","volume-title":"I Consenso Brasileiro para Boas Pr\u00e1ticas de Preparo da Terapia Antineopl\u00e1sica [First Brazilian consensus on good practices in antineoplastic therapy preparation]","author":"Brazilian Society of Oncology Pharmacists (SOBRAFO)","year":"2014","unstructured":"Brazilian Society of Oncology Pharmacists (SOBRAFO). I Consenso Brasileiro para Boas Pr\u00e1ticas de Preparo da Terapia Antineopl\u00e1sica [First Brazilian consensus on good practices in antineoplastic therapy preparation]. SOBRAFO, 2014."},{"key":"e_1_3_3_17_2","unstructured":"Federal Pharmacy Council (Brazil). Resolu\u00e7\u00e3o n\u00b0 640 de 27 de abril de 2017 [Resolution No. 640 of 27 April 2017]. Establishes the minimum qualification for pharmacists practising in oncology. Di\u00e1rio Oficial da Uni\u00e3o. 8 May 2017."},{"key":"e_1_3_3_18_2","unstructured":"Brazilian Health Regulatory Agency (ANVISA). Bul\u00e1rio Eletr\u00f4nico [Electronic drug labeling database] [Internet]. Bras\u00edlia: ANVISA https:\/\/consultas.anvisa.gov.br\/#\/bulario\/ (accessed 20 December 2024)."},{"key":"e_1_3_3_19_2","unstructured":"Brazil. Ministry of planning budget and management. Comprasnet: federal government procurement portal [Internet] https:\/\/www.comprasnet.gov.br\/acesso.asp?url=\/livre (2024 accessed 9 September 2024)."},{"key":"e_1_3_3_20_2","volume-title":"Exchange rates - US dollar (selling), PTAX quotation [Internet]","author":"Central Bank of Brazil","year":"2024","unstructured":"Central Bank of Brazil. Exchange rates - US dollar (selling), PTAX quotation [Internet]. Bras\u00edlia: BCB, 2024. https:\/\/www.bcb.gov.br\/estabilidadefinanceira\/historicocotacoes (accessed 17 September 2026)."},{"key":"e_1_3_3_21_2","unstructured":"Brazil. Ministry of Health. National Health Council. Resolu\u00e7\u00e3o n\u00b0 510 de 7 de abril de 2016 [Resolution No. 510 of 7 April 2016]. Provides for the rules applicable to research in the human and social sciences. Di\u00e1rio Oficial da Uni\u00e3o. 24 May 2016;Section 1:44."},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vhri.2015.08.001"},{"key":"e_1_3_3_23_2","volume-title":"StatPearls [Internet]","author":"Casale J","year":"2024","unstructured":"Casale J, Patel P. Fluorouracil. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024, https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK549808\/ (acesso em 23 jun. 2025)."},{"key":"e_1_3_3_24_2","volume-title":"Guia de protocolos e medicamentos para tratamento em oncologia e hematologia [Guide to protocols and medicines for oncology and hematology treatment]","author":"Hospital Israelita Albert Einstein","year":"2013","unstructured":"Hospital Israelita Albert Einstein. Guia de protocolos e medicamentos para tratamento em oncologia e hematologia [Guide to protocols and medicines for oncology and hematology treatment]. 1st ed. S\u00e3o Paulo: Hospital Israelita Albert Einstein, 2013."},{"key":"e_1_3_3_25_2","unstructured":"Hospital S\u00edrio-Liban\u00eas. Fluoruracila (5-FU) [Fluorouracil (5-FU)] [Internet]. Guia Farmac\u00eautico. S\u00e3o Paulo: Hospital S\u00edrio-Liban\u00eas 2018 https:\/\/guiafarmaceutico.hsl.org.br\/fluoruracila (accessed 29 July 2025)."},{"key":"e_1_3_3_26_2","volume-title":"Leucemia linfobl\u00e1stica aguda ganha novo tratamento [New treatment approved for acute lymphoblastic leukemia] [Internet]","author":"Brazilian Health Regulatory Agency (ANVISA)","year":"2022","unstructured":"Brazilian Health Regulatory Agency (ANVISA). Leucemia linfobl\u00e1stica aguda ganha novo tratamento [New treatment approved for acute lymphoblastic leukemia] [Internet]. Bras\u00edlia: ANVISA, 2022, https:\/\/www.gov.br\/anvisa\/pt-br\/assuntos\/noticias-anvisa\/2018\/leucemia-linfoblastica-aguda-ganha-novo-tratamento (accessed 18 January 2025)."},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1177\/10781552231221450"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40545-023-00518-3"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12175662"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1177\/10781552241230889"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/anae.70122"},{"key":"e_1_3_3_32_2","first-page":"277","article-title":"Gest\u00e3o de custos e res\u00edduos na utiliza\u00e7\u00e3o de quimioter\u00e1picos antineopl\u00e1sicos [Cost and waste management in the use of antineoplastic chemotherapy]","volume":"9","author":"Da Silva BQ","year":"2017","unstructured":"Da Silva BQ, Trombini MM, Da Silva JAC. Gest\u00e3o de custos e res\u00edduos na utiliza\u00e7\u00e3o de quimioter\u00e1picos antineopl\u00e1sicos [Cost and waste management in the use of antineoplastic chemotherapy]. J Bras Econ Saude 2017; 9: 277\u2013281.","journal-title":"J Bras Econ Saude"},{"key":"e_1_3_3_33_2","unstructured":"Castro AMA. O impacto de pol\u00edticas p\u00fablicas no acesso ao trastuzumabe para o tratamento de pacientes com c\u00e2ncer de mama em um hospital universit\u00e1rio [The impact of public policies on access to trastuzumab for breast cancer patients in a university hospital] [dissertation]. Ribeir\u00e3o Preto SP Brazil: Ribeir\u00e3o Preto Medical School University of S\u00e3o Pa 2020."},{"key":"e_1_3_3_34_2","first-page":"66","article-title":"Avalia\u00e7\u00e3o de riscos ambientais em hospitais: aplica\u00e7\u00e3o ao tratamento quimioter\u00e1pico [Environmental risk assessment in hospitals: application to chemotherapy treatment]","volume":"9","author":"Moura LL","year":"2015","unstructured":"Moura LL, Silva RF, Pontes AT, et al. Avalia\u00e7\u00e3o de riscos ambientais em hospitais: aplica\u00e7\u00e3o ao tratamento quimioter\u00e1pico [Environmental risk assessment in hospitals: application to chemotherapy treatment]. Rev Gest Soc Ambient 2015; 9: 66\u201381.","journal-title":"Rev Gest Soc Ambient"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1177\/10781552251369431"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.38677"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1177\/10781552251361801"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1177\/10781552261441848"},{"key":"e_1_3_3_39_2","first-page":"1","article-title":"Evaluation of cytotoxic drugs waste management in Gaza Strip hospitals","volume":"8","author":"Farroukh FF","year":"2025","unstructured":"Farroukh FF, El-Ashgar NM, Al-Madhon MI. Evaluation of cytotoxic drugs waste management in Gaza Strip hospitals. Isra Univ J Appl Sci 2025; 8: 1\u201322.","journal-title":"Isra Univ J Appl Sci"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/jppr.70023"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261497394","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552261497394","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261497394","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:55:33Z","timestamp":1792072533000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552261497394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,13]]},"references-count":39,"alternative-id":["10.1177\/10781552261497394"],"URL":"https:\/\/doi.org\/10.1177\/10781552261497394","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,13]]},"article-number":"10781552261497394"}}